Transformation of Sézary Syndrome Into CD30+ Anaplastic Large T-Cell Lymphoma After Alemtuzumab Therapy With Evidence of Clonal Unity. (January 2015)

• Record Type: Journal Article
• Authors: Nevet, Mariela Judith; Zuckerman, Tsila; Sahar, Dvora; Bergman, Reuven
• Is Part Of: American journal of dermatopathology. Volume 37:Number 1(2015)
• Publication Date: 2015-01
• Subjects: alemtuzumab -- lymphoma -- anaplastic; Skin -- Diseases -- Periodicals; Histology, Pathological -- Periodicals; 616.50705
• DOI: 10.1097/DAD.0000000000000156
• Languages: English
• ISSNs: 0193-1091

Abstract

Abstract : Abstract: Alemtuzumab is a humanized mouse antibody targeting the CD52 cell surface, which has been effective in patients with advanced stage mycosis fungoides (MF) including erythrodermic MF and Sézary syndrome. There are a few descriptions of large cell transformation after its administration. A young patient with an acute onset of Sézary syndrome treated initially unsuccessfully with fludarabine and cyclophosphamide and later on successfully with alemtuzumab has been described. Three weeks after the beginning of therapy, however, she developed transformed T-cell lymphoma indistinguishable from CD30 + anaplastic large-cell lymphoma. After bone marrow transplantation, the transformed CD30 + cutaneous T-cell lymphoma recurred as a transformed CD30 + plaque MF. All 3 types of lesions showed the same T-cell receptor clonal gene rearrangement, which supports the notion that Sézary syndrome, CD30 + anaplastic large-cell lymphoma, and MF are interrelated.